PremiumCompany AnnouncementsTourmaline Bio Announces Positive Phase 2 Trial Results Tourmaline Bio announces results from ongoing Phase 2 TRANQUILITY trial Buy Rating for Tourmaline Bio: Anticipated Catalyst from Phase 2 TRANQUILITY Study on Pacibekitug PremiumRatingsTourmaline Bio: Strong Financial Position and Promising Phase II Study Results Drive Buy Rating Tourmaline Bio reports Q1 EPS (89c), consensus (94c) Tourmaline Bio sees cash runway into 2H27 PremiumRatingsTourmaline Bio’s TOUR006: Potential Best-in-Class IL-6 Treatment with Strategic Market Positioning Positive Buy Rating for Tourmaline Bio Driven by Promising Pacibekitug Developments and Strategic Value Tourmaline Bio price target raised to $43 from $42 at Wedbush 
